Lena Miloradovic
CSL (Australia)(AU)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, vaccines and immunoinformatics approaches, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research
Most-Cited Works
- → Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans(2004)438 cited
- → Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery(2004)203 cited
- → Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma(2009)118 cited
- → Immunodominant CD4 + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant(2004)90 cited
- → A Pilot Study of Peripheral Blood BDCA-1 (CD1c) Positive Dendritic Cells Pulsed with NY-ESO-1 ISCOMATRIX™ Adjuvant(2017)17 cited
- Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C et al.. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465-2472(2005)
- → The Removal of Viruses During the Purification of Equine Antisera using Filtration Aids Hyflo Super-Cel™ and Fulmont™ Super A(2000)4 cited
- A phase 1 clinical trial of NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM® adjuvant) in patients with minimal residual disease(2003)
- NY-ESO-1 protein-based cancer vaccines: the Melbourne experience(2005)
- → Quantitation of immune responses against the cancer testis antigen NY-ESO-1 following vaccination with protein with and without ISCOMATRIX adjuvant(2004)1 cited